Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) insider Mauro Stocchi sold 13,649 shares of the business's stock in a transaction on Monday, September 28th. The shares were sold at an average price of €21.50, for a total transaction of €293,453.50. Following the sale, the insider directly owned 400,000 shares of the company's stock, valued at approximately €8,600,000. The trade was a 3.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Stevanato Group Stock Performance
Stevanato Group stock traded down €0.24 during trading on Wednesday, reaching €20.96. The company had a trading volume of 192,808 shares, compared to its average volume of 510,750. Stevanato Group S.p.A. has a 52 week low of €12.89 and a 52 week high of €27.99. The firm's 50-day simple moving average is €21.06 and its 200 day simple moving average is €18.37. The firm has a market capitalization of $6.35 billion, a price-to-earnings ratio of 37.42, a price-to-earnings-growth ratio of 1.75 and a beta of 0.75. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.21.
Stevanato Group (NYSE:STVN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported €0.14 earnings per share for the quarter, missing the consensus estimate of €0.15 by (€0.01). The company had revenue of €302.00 million for the quarter. Stevanato Group had a net margin of 10.99% and a return on equity of 10.43%. Sell-side analysts forecast that Stevanato Group S.p.A. will post 0.69 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on STVN shares. Wolfe Research started coverage on shares of Stevanato Group in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $21.00 target price on the stock. TD Cowen upgraded shares of Stevanato Group to a "strong-buy" rating in a research report on Wednesday, June 17th. UBS Group started coverage on shares of Stevanato Group in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $23.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Stevanato Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy".
Read Our Latest Report on Stevanato Group
Institutional Trading of Stevanato Group
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Conestoga Capital Advisors LLC boosted its stake in Stevanato Group by 7.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company's stock worth $116,762,000 after purchasing an additional 602,050 shares during the period. Wellington Management Group LLP purchased a new position in shares of Stevanato Group in the second quarter worth $22,621,000. Ranger Investment Management L.P. bought a new position in shares of Stevanato Group during the second quarter worth $21,438,000. Cooper Investors PTY Ltd. boosted its position in shares of Stevanato Group by 4.4% during the second quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company's stock worth $12,080,000 after acquiring an additional 28,265 shares during the last quarter. Finally, Sands Capital Management LLC grew its stake in Stevanato Group by 6.0% during the fourth quarter. Sands Capital Management LLC now owns 493,006 shares of the company's stock valued at $9,919,000 after acquiring an additional 28,075 shares in the last quarter.
About Stevanato Group
(
Get Free Report)
Stevanato Group S.p.A. is an Italy-based provider of drug-containment, drug-delivery and diagnostic solutions for the pharmaceutical, biotechnology and healthcare industries. The company serves customers across the development, production and administration of injectable medicines, with activities spanning pharmaceutical glass packaging, medical devices and manufacturing technologies.
Its product portfolio includes glass vials, cartridges, syringes and other primary containers, as well as ready-to-use packaging solutions such as EZ-fill.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stevanato Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.
While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
